Nuvation Bio Inc. (NUVB)

Market Cap	766.65M
Revenue (ttm)	1.44M
Net Income (ttm)	-510.72M
Shares Out	334.78M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	959,756
Open	2.290
Previous Close	2.300
Day's Range	2.220 - 2.370
52-Week Range	1.210 - 4.160
Beta	1.36
Analysts	Strong Buy
Price Target	6.17 (+169.43%)
Earnings Date	Nov 12, 2024

About NUVB

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC)...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 51
• Stock Exchange: NYSE
• Ticker Symbol: NUVB
• Website: https://www.nuvationbio.com

Analyst Forecast

According to 6 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price forecast is $6.17, which is an increase of 169.43% from the latest price.

Price Target

$6.17

(169.43% upside)

Analyst Consensus: Strong Buy